SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial-Reference-Cited by-同舟云学术

SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial

Published:2022-07 Issue:7 Volume:9 Page:e493-e503
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Song Yuqin,Liu Yanyan,Li Zhi-Ming,Li Lanfang,Su Hang,Jin Zhengming,Zuo Xuelan,Wu Jianyuan,Zhou Hui,Li Kunyan,He Chuan,Zhou Jianfeng,Qi Junyuan,Hao Siguo,Cai Zhen,Li Yijing,Wang Weiwei,Zhang Xiaojing,Zou Jianjun,Zhu Jun

Publisher

Elsevier BV

Subject

Hematology

Reference26 articles.

1. Aberrations of EZH2 in cancer;Chase;Clin Cancer Res,2011

2. The Polycomb complex PRC2 and its mark in life;Margueron;Nature,2011

3. Overcoming immune checkpoint blockade resistance via EZH2 inhibition;Kim;Trends Immunol,2020

4. Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy;Wang;Am J Clin Exp Urol,2019

5. EZH2 mutations are frequent and represent an early event in follicular lymphoma;Bödör;Blood,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual-target EZH2 inhibitor: latest advances in medicinal chemistry;Future Medicinal Chemistry;2024-07-31

2. EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer;Biomedicine & Pharmacotherapy;2024-06

3. Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice;Cancers;2024-05-10

4. Antitumoral Potential of the Histone Demethylase Inhibitor GSK-J4 in Retinoblastoma;Investigative Opthalmology & Visual Science;2024-02-23

5. Impact of Histone Lysine Methyltransferase SUV4-20H2 on Cancer Onset and Progression with Therapeutic Potential;International Journal of Molecular Sciences;2024-02-21